Search research articles
Contact Us
Filters
Showing results (91-100 of 147) with videos related to
Page
of 15
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 12, 2022
Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV
Edgar T Overton, Isabelle R Weir, Markella V Zanni, et al.
American Heart Journal
|
April 1, 2019
Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
Steven K Grinspoon, Kathleen V Fitch, Edgar Turner Overton, et al.
The Journal of Infectious Diseases
|
July 10, 2020
Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum
Laura M Smeaton, Emma M Kileel, Beatriz Grinsztejn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 24, 2023
Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)
Emma M Kileel, Carlos D Malvestutto, Janet Lo, et al.
AIDS (London, England)
|
June 21, 2024
Association of T-cell subtypes with macrophage-specific arterial infiltration in people with HIV
Samuel R Schnittman, Ria Talathi, Moses Q Wilks, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 16, 2021
Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial
Pamela S Douglas, Triin Umbleja, Gerald S Bloomfield, et al.
Blood Advances
|
January 10, 2024
Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial
Romit Bhattacharya, Md Mesbah Uddin, Aniruddh P Patel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 26, 2025
Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2
Steven K Grinspoon, Sophia Zhao, Esteban Martinez, et al.
JACC. Advances
|
May 15, 2025
Coronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE Substudy
Michael T Lu, Heather J Ribaudo, Sara McCallum, et al.
The Journal of Clinical Investigation
|
September 9, 2025
Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV
Márton Kolossváry, Irini Sereti, Markella V Zanni, et al.
Page
of 15
Search research articles
Search
Showing results (91-100 of 147) with videos related to
Sort By:
Page
of 15
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 12, 2022
Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV
Edgar T Overton, Isabelle R Weir, Markella V Zanni, et al.
American Heart Journal
|
April 1, 2019
Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
Steven K Grinspoon, Kathleen V Fitch, Edgar Turner Overton, et al.
The Journal of Infectious Diseases
|
July 10, 2020
Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum
Laura M Smeaton, Emma M Kileel, Beatriz Grinsztejn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 24, 2023
Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)
Emma M Kileel, Carlos D Malvestutto, Janet Lo, et al.
AIDS (London, England)
|
June 21, 2024
Association of T-cell subtypes with macrophage-specific arterial infiltration in people with HIV
Samuel R Schnittman, Ria Talathi, Moses Q Wilks, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 16, 2021
Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial
Pamela S Douglas, Triin Umbleja, Gerald S Bloomfield, et al.
Blood Advances
|
January 10, 2024
Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial
Romit Bhattacharya, Md Mesbah Uddin, Aniruddh P Patel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 26, 2025
Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2
Steven K Grinspoon, Sophia Zhao, Esteban Martinez, et al.
JACC. Advances
|
May 15, 2025
Coronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE Substudy
Michael T Lu, Heather J Ribaudo, Sara McCallum, et al.
The Journal of Clinical Investigation
|
September 9, 2025
Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV
Márton Kolossváry, Irini Sereti, Markella V Zanni, et al.
Page
of 15